FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2066526978> ?p ?o ?g. }

• W2066526978 endingPage "2584" @default.
• W2066526978 startingPage "2577" @default.
• W2066526978 abstract "Tumor necrosis factor-alpha (TNF-alpha) is an important cytokine involved in the pathogenesis of inflammatory bowel disease. The monoclonal antibody to TNF-alpha, infliximab, is effective in treating Crohn's disease. Preclinical studies suggest the importance of TNF-alpha in treating ulcerative colitis (UC). We report the effectiveness of infliximab for UC and examine factors predictive of response to medication.Data from all UC patients receiving infliximab at four institutions were analyzed. Disease activity was determined by the Disease Activity Index.A total of 27 patients with active UC received inpatient (37%) and outpatient (63%) infliximab as single (52%) or multiple (two to 15) infusions (48%). Twelve patients (44%) achieved remission and six patients (22%) had partial response. Nine patients had no response; five subsequently underwent total colectomy. The median time to achieve response and remission was 4 days and the median duration 8 wk. Nine of the 18 patients who responded experienced 19 relapses; 18 of these relapses (95%) were successfully treated with repeat infusions. Steroid-refractory patients were less likely to respond to infliximab therapy than were steroid-responsive patients (33% vs 83%; p = 0.026). No other factors were predictive of response to infliximab. Two patients developed serious adverse events, including death in one case.Preliminary evidence suggest effectiveness of infliximab in the treatment of UC, including medically refractory severe disease. Individuals who are refractory to corticosteroids, however, may be unlikely to respond to infliximab. A randomized controlled trial is necessary to further investigate the efficacy of infliximab in patients with UC." @default.
• W2066526978 created "2016-06-24" @default.
• W2066526978 creator A5012785273 @default.
• W2066526978 creator A5020827915 @default.
• W2066526978 creator A5034124536 @default.
• W2066526978 creator A5041936168 @default.
• W2066526978 creator A5044524314 @default.
• W2066526978 creator A5065162114 @default.
• W2066526978 creator A5070688316 @default.
• W2066526978 creator A5074364628 @default.
• W2066526978 creator A5089464953 @default.
• W2066526978 date "2002-10-01" @default.
• W2066526978 modified "2023-09-25" @default.
• W2066526978 title "Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis" @default.
• W2066526978 cites W180072684 @default.
• W2066526978 cites W1971087882 @default.
• W2066526978 cites W1985209162 @default.
• W2066526978 cites W1994153337 @default.
• W2066526978 cites W2014257728 @default.
• W2066526978 cites W2024162533 @default.
• W2066526978 cites W2038535814 @default.
• W2066526978 cites W2047398409 @default.
• W2066526978 cites W2049156339 @default.
• W2066526978 cites W2056879187 @default.
• W2066526978 cites W2065427609 @default.
• W2066526978 cites W2065791817 @default.
• W2066526978 cites W2071644653 @default.
• W2066526978 cites W2076376018 @default.
• W2066526978 cites W2091639856 @default.
• W2066526978 cites W2115518955 @default.
• W2066526978 cites W2118699343 @default.
• W2066526978 cites W2121650731 @default.
• W2066526978 cites W2163779489 @default.
• W2066526978 cites W2320941231 @default.
• W2066526978 cites W2321205867 @default.
• W2066526978 cites W2321453230 @default.
• W2066526978 cites W2322616832 @default.
• W2066526978 cites W2326330820 @default.
• W2066526978 cites W4232972499 @default.
• W2066526978 cites W4239224379 @default.
• W2066526978 cites W4313342450 @default.
• W2066526978 doi "https://doi.org/10.1111/j.1572-0241.2002.06026.x" @default.
• W2066526978 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12385442" @default.
• W2066526978 hasPublicationYear "2002" @default.
• W2066526978 type Work @default.
• W2066526978 sameAs 2066526978 @default.
• W2066526978 citedByCount "160" @default.
• W2066526978 countsByYear W20665269782012 @default.
• W2066526978 countsByYear W20665269782013 @default.
• W2066526978 countsByYear W20665269782014 @default.
• W2066526978 countsByYear W20665269782015 @default.
• W2066526978 countsByYear W20665269782016 @default.
• W2066526978 countsByYear W20665269782017 @default.
• W2066526978 countsByYear W20665269782018 @default.
• W2066526978 countsByYear W20665269782019 @default.
• W2066526978 countsByYear W20665269782020 @default.
• W2066526978 countsByYear W20665269782021 @default.
• W2066526978 countsByYear W20665269782022 @default.
• W2066526978 crossrefType "journal-article" @default.
• W2066526978 hasAuthorship W2066526978A5012785273 @default.
• W2066526978 hasAuthorship W2066526978A5020827915 @default.
• W2066526978 hasAuthorship W2066526978A5034124536 @default.
• W2066526978 hasAuthorship W2066526978A5041936168 @default.
• W2066526978 hasAuthorship W2066526978A5044524314 @default.
• W2066526978 hasAuthorship W2066526978A5065162114 @default.
• W2066526978 hasAuthorship W2066526978A5070688316 @default.
• W2066526978 hasAuthorship W2066526978A5074364628 @default.
• W2066526978 hasAuthorship W2066526978A5089464953 @default.
• W2066526978 hasConcept C121332964 @default.
• W2066526978 hasConcept C126322002 @default.
• W2066526978 hasConcept C141071460 @default.
• W2066526978 hasConcept C142424586 @default.
• W2066526978 hasConcept C17991360 @default.
• W2066526978 hasConcept C197934379 @default.
• W2066526978 hasConcept C2776667177 @default.
• W2066526978 hasConcept C2777138892 @default.
• W2066526978 hasConcept C2778260677 @default.
• W2066526978 hasConcept C2779134260 @default.
• W2066526978 hasConcept C2779280984 @default.
• W2066526978 hasConcept C2780479503 @default.
• W2066526978 hasConcept C71924100 @default.
• W2066526978 hasConcept C87355193 @default.
• W2066526978 hasConcept C90924648 @default.
• W2066526978 hasConceptScore W2066526978C121332964 @default.
• W2066526978 hasConceptScore W2066526978C126322002 @default.
• W2066526978 hasConceptScore W2066526978C141071460 @default.
• W2066526978 hasConceptScore W2066526978C142424586 @default.
• W2066526978 hasConceptScore W2066526978C17991360 @default.
• W2066526978 hasConceptScore W2066526978C197934379 @default.
• W2066526978 hasConceptScore W2066526978C2776667177 @default.
• W2066526978 hasConceptScore W2066526978C2777138892 @default.
• W2066526978 hasConceptScore W2066526978C2778260677 @default.
• W2066526978 hasConceptScore W2066526978C2779134260 @default.
• W2066526978 hasConceptScore W2066526978C2779280984 @default.
• W2066526978 hasConceptScore W2066526978C2780479503 @default.
• W2066526978 hasConceptScore W2066526978C71924100 @default.
• W2066526978 hasConceptScore W2066526978C87355193 @default.
• W2066526978 hasConceptScore W2066526978C90924648 @default.

• next